Skip to main content

BioMedNewsBreaks – Psycheceutical Bioscience Inc. (BWVI) Inks Agreement for First-Ever Clinical Trials of a Proprietary Ketamine Topical Cream to Treat PTSD

Psycheceutical Bioscience (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, has entered into an exclusive agreement with iNGENū Pty Ltd., an Australian-based contract research organization. The agreement calls for iNGENū to conduct ​two human ​clinical trials of BWVI’s patented NeuroDirect(TM) ketamine topical ​in Australia. The first, a phase 1 trial, is designed to study 20 people and evaluate the safety, tolerability and pharmacokinetics of a single dose of NeuroDirect ketamine; the second, a phase 2 trial, is designed to study 115 participants diagnosed with post-traumatic stress disorder (“PTSD”) to evaluate the effectiveness of NeuroDirect ketamine on treating their symptoms. “We’re thrilled to have partnered with iNGENū as we move our proprietary delivery technology into human clinical trials,” said Psycheceutical Bioscience CEO Chad Harman in the press release. “iNGENū is an industry-leading, full-service CRO providing end-to-end services for companies like ours developing psychedelic drugs. Together, we’re committed to discovering new psychedelic therapies for mental health disorders and central nervous system diseases. We’re eager to engage in this next phase of the development of ​​​​our NeuroDirect delivery system, which we’re designing to solve the issues with side effects that most psychedelic drug development companies face, while at the same time developing lifesaving mental health treatments.​​”

To view the full press release, visit

About Psycheceutical Bioscience Inc. 

Psycheceutical Bioscience is developing cutting-edge technologies to advance the safe and effective delivery of psychedelic pharmaceutical medicines. Powered by a team of FDA drug-development veterans, biotechnology experts and top minds in the psychedelic industry, Psycheceutical is on a mission to commercialize its precision-dosing technologies to provide affordable, life-saving treatments to anyone suffering from mental health disorders or central nervous system diseases. For more information about the company, please visit

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.